Search
mirabegron (Myrbetriq)
FDA-approved June 2012
Indications:
- treatment of overactive bladder
- urinary urgency, urinary frequency
Contraindications:
- hypertension
- end-stage renal disease
- hepatic insufficiency
Dosage:
- 25-50 mg P QD
Tabs: 25, 50 mg
Pharmacokinetics:
- inhibits CYP2D6
Adverse effects:
- hypertension
- nasopharyngitis
- urinary tract infection
- constipation
- fatigue
- tachycardia
- abdominal pain
- not associated with increased risk of cardiac arrhythmia, stroke or myocardial infarction relative to other pharmaceuticals for overactive bladder
- does not affect the CNS & is not associated with cognitive changes
Drug interactions:
- may increase plasma levels of drugs metabolized by CYP2D6
- metoprolol, desipramine,
- increases plasma levels of digoxin
Mechanism of action:
- beta-3 adrenergic receptor agonist
- relaxes the bladder muscle during filling, thus increasing bladder storage capacity
Notes:
- cost ~ $210/month in 2012
Interactions
drug adverse effects of adrenergic receptor agonists
General
smooth muscle relaxant
beta-3 adrenergic receptor agonist
Database Correlations
PUBCHEM correlations
References
- FDA News Release: June 28, 2012
FDA approves Myrbetriq for overactive bladder
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm310096.htm
- Prescriber's Letter 19(10): 2012
Detail-Document#: 281026
(subscription needed) http://www.prescribersletter.com
CHART: Medications for Overactive Bladder
- Tadrous M, Matta R, Greaves S et al
Association of Mirabegron With the Risk of Arrhythmia in Adult
Patients 66 Years or Older - A Population-Based Cohort Study.
JAMA Intern Med. Published online July 15, 2019.
JAMA Intern Med. Published online July 15, 2019.
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2737915
Component-of
mirabegron/solifenacin (Myrbetriq/Vesicare)